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ABSTRACT 
Acute leukaemia  are usually rapidly progressive with death often occurring in a few weeks to a few months in 
untreated patients as a result of abnormal hematopoietic function as well as impaired immune response. The 
risk of relapse which remains in 20% of patients in remission calls for more research on acute leukaemia. This 
study therefore, evaluated the plasma levels of nitric oxide (NO), interleukin-4 (IL-4), interferon-gamma (IFN-γ) 
and immunoglobulin classes (IgA, IgG, IgM, IgE) in twenty-five (25) patients with acute leukaemia (AL) and 
twenty-five (25) apparently healthy controls. The mean levels of plasma IgA, IgG and IgM were not significantly 
elevated in leukaemia patients compared with control. However, the mean plasma levels of IgE, NO, IL-4 and 
IFN-γ were significantly elevated in leukaemia patients compared with controls. It could therefore be concluded 
from this study that humoural immunity is not depressed in acute leukaemia patients.  
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INTRODUCTION 
Leukaemia is malignant neoplasm that is primarily 
bone marrow and peripheral blood-based. Stage of 
differentiation and clinico-pathological 
characteristics classify leukaemia into different 
classes such as myeloid, lymphoblastic, lymphoid, 
acute and chronic. In 2000, approximately 256,000 
children and adults around the world developed 
some form of leukaemia, and 209,000 died from it 
(Mathers et al., 2001).  Acute leukaemia (AL) may 
result in loss of normal hematopoietic function of 
the bone marrow, with development of anaemia, 
thrombocytopenia, and granulocytopenia.  
 
Development of malignancies such as leukaemia 
indicates a dysregulation in the immune system 
(McClain, 1996) and hematologic malignancies have 
been shown to be one of the important causes of 
secondary immunodeficiency (Rosenblatt, 1996). 
Hyperactive immune response and immune 
inactivity have both been emphasised in the 
pathogenesis of acute leukaemia (Narita et al., 
2001). There has been conflicting reports on 
quantitative and qualitative immunologic variables 
in malignancies especially; serum immunoglobulin 
levels (Potapnev et al., 2004). Reports showed that 
there was no significant difference in mean values 
of serum immunoglobulin classes in patients with 
acute lymphoblastic leukaemia (ALL) compared 
with age matched healthy subjects (Haraldsson et 
al., 1994). 
 
Nitric oxide (NO) is a free radical molecule which is 
produced in macrophages, neutrophils and 
lymphocytes (Brunne et al., 1997). Significant 
activity of inducible nitric oxide synthase (NOS) has 
been reported in tumour cells, including acute and 
chronic leukemic cells (Brandao et al., 2001). 
Cytokines are released in response to a diverse 
range of cellular stresses that profoundly affect 
several stages of cancer formation, growth of 
tumours in vivo, progression and playing a
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significant role in immuno-surveillance against 
malignant cells (Colombo and Trinchieri, 2002). In 
acute leukaemia patients, cytokines could be 
produced both by leukemic and normal cells 
(Cloppenborg et al., 2005; Wu et al., 2005). 
Cytokines have been reported to be important 
regulators of blast proliferation, but the responses 
to cytokines have been variable (Bruserud, 1998), 
therefore the roles of cytokines in the pathogenesis 
of acute leukaemia is unclear.  
 
IFN-γ is reported to influence many biological 
processes along with the production of NO2- and 
iNOS in certain tumours (Alexandrova et al., 2001). 
Ghosh et al. (2004) observed about three to four 
fold increase in IFN- γ level patients with acute 
lymphoblastic patients. Interleukin-4 (IL-4) is 
produced within the bone marrow 
microenvironment either by non-resident 
circulating cells, namely T lymphocytes, mast cells, 
and basophils or by bone marrow stromal cells 
(Cardoso et al., 2009). Importantly, IL-4 induces 
proliferation of T-cell acute lymphoblastic 
leukaemia (T-ALL) cells (Barata et al., 2004). The 
exact mechanisms by which IL-4 induces leukaemia 
expansion remain unknown but Cardoso et al. 
(2009) suggested that inhibition of IL-4 signalling 
may have therapeutic potential in T-cell leukaemia 
since it mediates the proliferation of T-cell acute 
lymphoblastic leukaemia cells through mTOR-
dependent regulation of cell cycle progression.  
 
Although current treatment regimen cures almost 
80% of cases, the risk of relapse in 20% of patients 
is a great concern. Therefore, there is a need to 
further elucidate the disease biology in acute 
leukaemia so as to provide information for the first 
time on the concept of immune status in acute 
leukaemia patients in Nigeria. To achieve this, we 
determined plasma levels of innate humoural 
factors (IFN-gamma, IL-4 and NO) and adaptive 
humoural factors (Ig G, A, M, E) in a cohort of 
leukaemia patients. 
 
MATERIALS AND METHODS 
Patients  
The design is a case control study. Twenty five (25) 
patients with acute leukaemia [14 Acute 
Lymphoblastic Leukaemia (ALL) and 11 Acute 
Myeloblastic Leukaemia (AML)], with the age range 
of 4 to 50 years were recruited for this study from 
the Haematology Outpatient Unit of the University 
College Hospital, Ibadan, Nigeria between March, 
2008 and November, 2010. The patients were 
taking no anti-leukemic therapy and were newly 
diagnosed cases. Twenty five age-matched healthy 
subjects were taken as control group. Informed 
consent was obtained from each participant and the 
study was approved by the University of 
Ibadan/University College Hospital (UI/UCH) Joint 
Ethical Review Committee. 
 
Biochemical Measurements 
Five millilitres (5ml) of venous blood were 
collected into heparinised bottles to obtain plasma 
after centrifugation for 5 minutes at 4000 x g. The 
plasma obtained was stored at -200C until analysed.  
 
Determination of Immunoglobulin Classes (IgG, 
IgM and IgA) 
Immunoglobulin G, A, and M were determined using 
single radial immunodiffusion as previously 
described (Arinola et al., 2006). The diameter of 
precipitin ring formed after antigen-antibody 
reaction in a buffered agar gel is proportional to the 
concentration of each parameter present in the 
plasma. Briefly, appropriately measured volume of 
diluted mono-specific antiserum, specific for each 
parameter, was properly mixed with noble agar and 
poured on glass plate. Wells of equal diameter were 
made in the antibody/agar gel and filled with 
standards (25%, 50%, 100%, and 200%) or test. 
The plates were incubated for 4 hours (IgG) and 18 
hours (IgA and IgM) at room temperature and the 
diameters of precipitin rings were measured using 
an illuminated Hyland viewer with a micrometre 
eyepiece. 
 
Determination of IgE 
Enzyme linked Immunosorbent Assay (MICRO-
ELISA, Leinco Technologies, Inc. USA) was used in 
determining the levels of IgE in the plasma (Barbee 
et al., 1981). The assay system utilises two unique 
antibodies (a mouse monoclonal and a goat 
polyclonal) directed against distinct antigenic 
determinants on the IgE molecule. Undiluted test 
samples/controls containing IgE were added to 
plastic wells coated with anti-IgE (mouse 
monoclonal) to form immune complexes. Anti-IgE 
(goat polyclonal) enzyme-labelled with horseradish 
peroxidase was added to each well and incubated 
for 45 minutes at room temperature. Enzyme 
chromogen and stopper solutions were added to 
the wells at room temperature. The intensity of the 
colour is directly proportional to the concentration 
of IgE in the sample. The optical density (OD) was 
read at 450nm wavelength and the OD of samples 
was used to extrapolate the concentration of IgE
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from the standard curve plotted with OD versus 
standard IgE concentrations. 
 
Determination of Nitric Oxide 
Nitric oxide was measured spectrophotometrically 
as the stable metabolite nitrite (NO2-) according to 
the Griess method (Green et al., 1982). Griess 
reagent (1% sulphanilamide and 0.1% 
naphthylethylenediamine dihydrochloride in 2% 
phosphoric acid) was mixed 1:1 with samples. 
Nitrite formed a coloured chromophore with the 
reagent which was measured with an ELISA 
microplate reader at 543 nm. The ELISA kit 
(G2930) was supplied by Promega, USA. 
 
Determination of IL-4 and IFN-γ 
Plasma levels of IL-4 and IFN-γ were determined 
using ELISA following manufacturer’s instruction 
(MICRO-ELISA, Leinco Technologies, Inc. USA). 
 
Statistical Analysis 
Statistical Package for the Social Sciences for 
Windows (SPSS, version 15.0) was used to analyse 
results expressed as mean ± SD. Student t-test was 




Table 1 shows that the mean levels of IgE, NO, IL-4 
and IFN-gamma were significantly raised in 
Nigerian patients with acute leukaemia compared 
with controls. The levels of IgA, IgG and IgM were 
not significantly different in the patients compared 
with the controls. 
 
Table 1: Levels (mean ± SD) of IgA, IgG, IgM, IgE, NO, IL-4 and IFN-γ in Leukaemia Patients and Controls 
 
Parameters 
(unit of measurement) 
Leukaemia 
  (n = 25) 
Control  









2.13 ± 2.40 
14.48 ± 7.56 
1.38 ± 0.64 
0.31± 0.03 
33.12 ± 19.61 
5.9 ± 0.4 
15.0 ± 9.0 
 2.50 ± 2.63 
 12.26 ± 6.38 
 1.56 ± 0.63 
 0.29 ± 0.02 
15.96 ± 10.69 
2.7 ± 0.2 















*P is significant at p < 0.05 value (2-tailed). 
 
DISCUSSION 
Acute leukaemia is a progressive clonal disorder 
that is driven by mutations (Lichtman and Liesveld, 
2001). Hyperactive immune response and immune 
inactivity have been emphasised in the 
pathogenesis of acute leukaemia (Narita et al., 
2001). In this study, no significant statistical 
difference was observed in the plasma levels of IgA, 
IgG and IgM in leukaemia patients compared with 
controls. This supports the reports of Okpala and 
Salimonu (1994) and Mashhadi et al. (2009). The 
normal level of serum IgG at diagnosis was found to 
be a beneficial prognostic factor associated with 
lower rate of leukemic cell persistence in peripheral 
blood and better outcome of childhood B-lineage 
ALL (Potapnev et al., 2004). In an older study, there 
was depression of both cellular immunity, 
measured by the number of T cells and skin tests, 
and humoral immunity, measured by number of B 
cells, primary antibody production to typhoid 
vaccine, and levels of immunoglobulin (Guy et al., 
1976). 
In contrast, mean plasma level of IgE was 
significantly higher in leukaemia patients compared 
with controls. This contradicts the report of Alsabti 
(1979) who observed no significant difference in 
acute myelogenous leukaemia patients. The 
differences observed could be due to differences in 
the immunopathological basis of acute 
lymphoblastic leukaemia  and acute myeloid 
leukaemia since this present study did not separate 
the patients into acute lymphocytic- or acute 
myeloid- patients.  
 
Cytokines are released in response to a diverse 
range of cellular stresses that profoundly affect 
several stages of cancer formation, growth of 
tumours in vivo, progression and playing a 
significant role in immunosurveillance against 
malignant cells (Colombo and Trinchieri, 2002). 
Significant elevation of plasma levels of NO, IFN-γ 
and IL-4 were observed in leukaemia patients 
compared with controls. The observed elevated 
level of IFN-γ corroborates the report of Ghosh et al. 
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(2004) but contradicts the report of Park et al. 
(2006). The observed elevation could be due to the 
presence of ligands for 9-O-AcSAa2-6GalNAc 
glycotope in acute leukaemia patients’ serum which 
is involved in regulating the functional level of IFN-
γ (Ghosh et al., 2004). More so, cellular stresses 
associated with leukaemia could induce IFN-γ 
production especially as IFN-γ is associated with 
lineage commitment and differentiation of the 
leukemic cells (Cloppenborg et al., 2005; Wu et al., 
2005). 
 
IL-4 is a growth factor that displays multiple 
biological activities which depends on cell target 
and its activation state. It has been reported to 
possess divergent effects on leukemic progenitors 
(Manabe et al., 1994). Elevated level of IL-4 
observed in this study supports the report of Park 
et al. (2006). This elevation might be a result of its 
antitumor effects and ALL cells growth suppression 
(Rossi et al., 2002). A similar observation was 
reported in chronic lymphocytic Leukaemia 
patients by Levesque et al. (2006). IL-4 exerts its 
suppressive activity by blocking the production of 
autocrine or paracrine growth promoting cytokines, 
which cooperate in the growth of neoplastic cells in 
vitro, as well as by direct inhibition on the growth 
of neoplastic cells. 
 
Although nitric oxide has cytotoxic and cytostatic 
properties in the tumoricidal activity of the immune 
system, studies have indicated that NO can be an 
important mediator of tumour growth (Jenkins et 
al., 1995). Elevated plasma level of NO was 
observed in this study. This is in line with report of 
Ghaffari et al. (2005). Tanaka et al. (2002) also 
reported a similar observation in NO related 
substrates in some haematological malignancies. 
The observed elevation could be due to the raised 
level of IFN-γ since IFN-γ influences the production 
of NO2- and iNOS in certain tumours (Alexandrova 
et al., 2001). Additionally, elevated level of IL-4, in 
conjunction with IFN-γ could also be responsible 
for the elevated NO since both was reported to 
induce iNOS expression in leukemic cells (Levesque 
et al., 2003). 
 
Patients with acute leukaemia are 
immunosuppressed, and this plays a major role in 
increasing their morbidity and mortality (Hersh et 
al., 1971). Also, immunosuppression is an obstacle 
to the treatment because immune mechanisms are 
thought to be important for the control of minimal 
residual disease (Serody et al., 1997). In the present 
study, the levels of immunoglobulin classes (IgG, A 
and M) and cytokine (interferon-gamma and 
interleukin-4) are not reduced in acute leukaemia  
patients, therefore the concept of immune 
suppression in acute leukaemia  patients might 
have been caused by other factors apart from 
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